Full-Time
Clinical Project Associate
Relay Therapeutics
201-500 employees
Drug discovery platform targeting protein motion
Compensation Overview
$61k - $87k/yr
Cambridge, MA, USA
In Person
Bachelor's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Relay Therapeutics
See people who can refer or advise you
- Bachelor’s degree with at least 2+ years of relevant clinical trial experience (e.g. CRO, Sponsor experience, clinical site or clinical trial vendor).
- Familiar with GCP and ICH Guidelines and the application to the conduct of clinical trials
- Motivated self-starter who can flourish in a fast-paced small company environment.
- Creative problem-solver with excellent communication and public speaking skills.
- Familiar with MS Office products (MS Project, Excel and Power Point)
- Strong interpersonal and organizational skills, with a high degree of attention to detail.
- Pragmatic and demonstrated ability to manage multiple competing tasks and demands
- Partner with Clinical Project Managers to support the day-to-day operations of clinical trial execution, with a focus on site start-up, study participant enrollment, clinical monitoring, GCP and protocol compliance, from the clinical sites, CROs and vendors.
- Serve as a point of contact for CROs, vendors, investigators and clinical site staff to support trial deliverable, effective communication and strong working relationships
- Develop ,maintain and improve study tracking tools
- Assist with vendor and site invoice review as well as budget management and tracking.
- Review and contribute to key study documents including, but not limited to, training records, regulatory packets, informed consent forms, case report forms, study oversight committee charters, and study plans.
- Maintain version control and documentation across clinical materials.
- Coordinate and track trial-specific equipment and supplies, as appropriate.
- Coordinate trial team meetings, including schedules, distribution, agendas, minutes and action items as well as actively participate in team meetings providing updates on your key responsibilities.
- Help to ensure the Trial Master File (TMF) is up-to-date and inspection ready.
- Support inspection readiness by collaborating with CROs and providing support to clinical sites to prepare for and respond to audit/inspection findings conducted by internal QA and external regulatory agencies.
- Actively participate in the development of department initiatives; contribute ideas to department initiatives that will make a difference to the efficiency and effectiveness of Clinical Operations.
Relay Therapeutics uses its Dynamo platform to discover drugs by exploring how proteins move, enabling them to target proteins previously considered undruggable. The platform blends experimental data with computational modeling to identify and optimize therapeutic candidates, with a focus on precision oncology and genetic diseases. Its approach combines motion biology, data-driven design, and active partnerships (such as a worldwide license and collaboration with Genentech) with an internal drug pipeline. The company aims to bring life-changing medicines to patients by advancing clinical trials and securing licensing collaborations to fund and validate its therapies.
Company Size
201-500
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2016
Get referred to Relay Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 cash reached $910.9 million, funding operations into 2029 without immediate financing pressure.
- May 19, 2026 ReInspire data showed 60% volumetric response and opened expansion cohorts.
- August 6, 2026 management picked zovegalisib-atirmociclib for 1L breast cancer, with Phase 3 planned early 2027.
What critics are saying
- ReDiscover-2 pits zovegalisib against capivasertib; Phase 3 reads through 2028 decide the franchise.
- Zovegalisib concentration is extreme; one trial failure wipes Relay's only near-term commercial path.
- The 2031 study completion timeline leaves years of dilution risk if investor sentiment weakens again.
What makes Relay Therapeutics unique
- Dynamo platform still targets intractable proteins through motion-based allostery, not brute-force screening.
- Zovegalisib became FDA Breakthrough Therapy designated on February 2026 for PIK3CA-mutant breast cancer.
- Relay owns full global rights on zovegalisib while Pfizer supplies atirmociclib for triplet development.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical, dental, vision
Life, disability, & FSA
401k
Commuter benefits
Parental leave
Home office stipend
Tuition reimbursement
PTO
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -4%2 year growth
↓ -5%Relay Therapeutics (NASDAQ:RLAY) posts quarterly earnings results, misses estimates by $0.02 EPS. August 8, 2026 Key points. * Relay Therapeutics reported a quarterly loss of $0.41 per share, missing analysts' estimate by $0.02, while revenue of $0.35 million fell short of the $0.96 million consensus. * Shares rose to $19.77, near the company's 52-week high of $20.79. Analysts maintain a "Moderate Buy" consensus, with an average price target of $25.17. * Institutional investors own approximately 96.98% of the stock, while company insiders sold 427,356 shares worth about $7.46 million over the past quarter. * Five stocks to consider instead of Relay Therapeutics. Relay Therapeutics (NASDAQ:RLAY - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02), FiscalAI reports. The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.96 million. Relay Therapeutics price performance. NASDAQ RLAY traded up $0.02 during mid-day trading on Friday, reaching $19.77. The stock had a trading volume of 2,315,168 shares, compared to its average volume of 2,222,666. Relay Therapeutics has a 1 year low of $3.03 and a 1 year high of $20.79. The stock has a market cap of $3.79 billion, a PE ratio of -12.59 and a beta of 1.69. The company has a fifty day moving average price of $17.71 and a 200 day moving average price of $13.48. Insiders place their bets. In other Relay Therapeutics news, CEO Sanjiv Patel sold 48,199 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $19.58, for a total transaction of $943,736.42. Following the sale, the chief executive officer directly owned 615,898 shares in the company, valued at approximately $12,059,282.84. This trade represents a 7.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Thomas Catinazzo sold 1,459 shares of the business's stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total value of $27,151.99. Following the completion of the transaction, the chief financial officer owned 158,285 shares of the company's stock, valued at $2,945,683.85. This represents a 0.91% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 427,356 shares of company stock valued at $7,461,240. 5.04% of the stock is currently owned by company insiders. Institutional trading of Relay Therapeutics. Institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC raised its holdings in shares of Relay Therapeutics by 11.9% during the first quarter. AQR Capital Management LLC now owns 364,946 shares of the company's stock valued at $956,000 after purchasing an additional 38,812 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Relay Therapeutics by 6.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company's stock worth $221,000 after purchasing an additional 5,238 shares during the last quarter. Millennium Management LLC boosted its holdings in Relay Therapeutics by 14.6% in the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company's stock worth $7,710,000 after purchasing an additional 374,491 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Relay Therapeutics in the 1st quarter worth approximately $53,000. Finally, Woodline Partners LP grew its position in Relay Therapeutics by 448.4% in the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company's stock worth $3,979,000 after purchasing an additional 1,241,657 shares during the period. Hedge funds and other institutional investors own 96.98% of the company's stock. Analyst upgrades and downgrades. A number of equities analysts have issued reports on the stock. Barclays boosted their price objective on shares of Relay Therapeutics from $27.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday. Wall Street Zen raised Relay Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 6th. The Goldman Sachs Group boosted their price target on Relay Therapeutics from $22.00 to $31.00 and gave the company a "buy" rating in a report on Tuesday, July 21st. Wells Fargo & Company upped their price target on Relay Therapeutics from $17.00 to $21.00 and gave the company an "overweight" rating in a research report on Tuesday, April 28th. Finally, Canaccord Genuity Group started coverage on shares of Relay Therapeutics in a report on Thursday, July 16th. They issued a "buy" rating and a $29.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $25.17. Discover more American Consumer News MarketBeat Portfolio Tools Stock Profit Calculator About Relay Therapeutics. Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins. The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing - including molecular dynamics simulations - with advanced experimental techniques such as cryo-electron microscopy and biophysical screening. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Relay Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list. While Relay Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Relay Therapeutics shares surge 20% on ASCO momentum for zovegalisib breast cancer program. Relay Therapeutics gains investor interest with promising data on its lead cancer therapy at ASCO 2026. Published 06/03/26 AT 12:16 AM AEST NEW YORK - Relay Therapeutics Inc. shares climbed more than 20% in morning trading Tuesday, reaching $17.12 as investors responded to ongoing buzz around the company's precision oncology pipeline at the American Society of Clinical Oncology annual meeting in Chicago. The clinical-stage biotechnology company, focused on small molecule therapies for cancer and genetic diseases, has seen renewed interest in its lead candidate zovegalisib (RLY-2608), a mutant-selective PI3Kα inhibitor. The stock's sharp move comes amid broader sector enthusiasm for oncology advancements showcased at the May 29-June 2 gathering. Zovegalisib continues to generate attention following earlier data readouts demonstrating clinically meaningful progression-free survival in PIK3CA-mutated, HR+/HER2- metastatic breast cancer. The program holds FDA Breakthrough Therapy designation, signaling regulatory recognition of its potential. Clinical Progress on Zovegalisib Updated interim results from the Phase 1/2 ReDiscover trial previously showed a median progression-free survival of 11.0 months in second-line patients treated with zovegalisib plus fulvestrant. Objective response rates reached 39% overall in patients with measurable disease, with consistent efficacy observed across kinase and non-kinase PIK3CA mutations. These findings, initially highlighted at prior scientific meetings, underscore zovegalisib's differentiated profile compared to non-selective PI3K inhibitors, which have faced challenges with toxicity such as hyperglycemia. The ongoing Phase 3 ReDiscover-2 trial evaluates the combination in CDK4/6-experienced patients. At ASCO 2026, Relay's presence contributes to the narrative of advancing targeted therapies in areas with significant unmet need. Approximately 40% of HR+/HER2- advanced breast cancer patients harbor PIK3CA mutations, often facing limited options after CDK4/6 inhibitor progression. Pipeline Expansion and Additional Data Beyond breast cancer, Relay has advanced zovegalisib into PIK3CA-driven vascular anomalies. Initial Phase 2 ReInspire trial results presented earlier highlighted encouraging safety and efficacy signals in this rare disease setting. The company's Dynamo platform, which integrates computational and experimental approaches to target protein motion, underpins its discovery efforts. This technology aims to address previously intractable targets through allosteric modulation. Relay also maintains a broader pipeline, including earlier-stage programs in oncology and genetic diseases, though zovegalisib remains the primary value driver. Financial Position Strengthened Relay reported $642.1 million in cash, cash equivalents and investments as of March 31, 2026, up from $554.5 million at year-end 2025. The increase followed net proceeds from at-the-market offerings. A subsequent May public offering added approximately $296.8 million in net proceeds. Management has stated that current resources provide runway into 2029, supporting continued clinical execution. First-quarter 2026 revenue was $3.0 million, primarily from a licensing agreement, with a net loss of $73.3 million. Analyst and Market Sentiment Wall Street maintains a generally positive stance on Relay, with consensus price targets around $21-$23. Ratings lean toward buy, reflecting optimism around zovegalisib's potential in a large addressable market. The stock's recent volatility aligns with typical biotech patterns tied to clinical catalysts. Tuesday's volume spike reflects heightened investor interest amid ASCO presentations across the oncology sector. Challenges and Competitive Landscape The PI3Kα space remains competitive, with other agents like capivasertib approved in similar settings. Relay's mutant-selective approach seeks to offer improved tolerability while maintaining efficacy, a key differentiator if Phase 3 data confirm earlier signals. Risks include clinical execution, regulatory outcomes, manufacturing scalability and broader biotech funding dynamics. Any data readouts showing efficacy compression or unexpected toxicities could pressure the stock. Broader Industry Context ASCO 2026 has featured multiple advances in targeted therapies and combination approaches for lung cancer, sarcoma and other malignancies. Positive momentum across oncology names has supported sector sentiment despite macroeconomic uncertainties. Relay's strategy positions it at the intersection of precision medicine and computational drug design. Success with zovegalisib could validate the platform and open opportunities for additional programs. Investment Considerations At current levels near $17, Relay trades with elevated expectations for its lead asset. The company's cash position provides flexibility for business development or accelerated development timelines. However, as a pre-commercial entity, it carries typical biotech risks including binary clinical outcomes. Financial advisors recommend careful position sizing given volatility. Diversification across the sector and attention to upcoming milestones, including potential conference updates and Phase 3 progress, remain important. Management will participate in upcoming investor conferences, including the Jefferies Global Healthcare Conference on June 3 and Goldman Sachs on June 8, providing further opportunities to discuss strategy. Relay Therapeutics enters the second half of 2026 with key data catalysts and a strengthened balance sheet. Whether Tuesday's gains hold will depend on sustained positive sentiment from ASCO, execution on the zovegalisib program and broader market conditions. The company's focus on transforming drug discovery through motion-based insights offers a compelling long-term narrative. As clinical programs mature, Relay could emerge as a significant player in precision oncology if it delivers on its pipeline promise. MEET IBT NEWS FROM BELOW CHANNELS
Relay Therapeutics, a clinical-stage precision medicine company, has priced an underwritten public offering of 22,916,667 shares at $12 per share. Underwriters exercised their full option to purchase an additional 3,437,500 shares, bringing gross proceeds to approximately $316 million before deducting fees and expenses. The company develops small molecule therapies for cancer and genetic diseases using its Dynamo platform. Its lead asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor in clinical development, currently in a Phase 3 trial for metastatic breast cancer. The drug is also being studied for genetic vascular anomalies. Goodwin's Life Sciences team advised on the transaction, led by Gabriela Morales-Rivera, Kristin Yeakel, Megan Riley, Caleb Paasche and Bill Collins.
Relay doubles the bar, outpacing Novartis with a 60% response in rare disease. Posted on May 20, 2026 By News Team Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics' PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval. Relay's investigational PI3KA inhibitor has elicited a 60% response rate in patients with vascular malformations, toppling Novartis' 11% overall response rate seen in a failed Phase 2 study of Vijoice. The biotech's execs are now looking to the FDA's accelerated approval pathway for the oral PI3KA inhibitor, called zovegalisib, pending additional data and feedback from regulators. The early-stage data include adults and children older than 12 years with vascular anomalies - an umbrella term for rare disorders marked by abnormal development of blood vessels, lymphatic vessels and nearby tissues. As of April 15, 32 patients were enrolled in the Phase 2 ReInspire trial, of which 22 patients had PIK3Ca-related overgrowth spectrum (PROS) - disorders caused by mutations in the PI3Ka gene. Of 20 evaluable patients, 12 - or 60% - achieved a volumetric response at 12 weeks, according to data set for presentation Wednesday at the International Society for the Study of Vascular Anomalies World Congress 2026. The overall response rate (ORR) doubles Leerink Partners' "prior bar for success" of 20%-25% ORR and is higher than the 11% ORR seen at week 16 for Novartis' oral PI3K inhibitor Vijoice in a failed PROS study. After Relay's data cutoff of April 15, one additional patient had an unconfirmed response, resulting in a 65% (13/20) ORR, according to the Cambridge, Massachusetts-based biotech. The data show "the full potential of what a mutant selective inhibitor can do in these vascular anomaly patients," Relay CEO Sanjiv Patel said on a Tuesday conference call. "[We] believe this leaves very little room for improvement of our volumetric response rate for anyone that will come behind us." At 12 weeks, interim investigator-measured impressions of change showed 89% of patients experiencing clinical improvement, while patient reports for the same metric were 79%. Pain scores, as measured by investigators, demonstrated clinical improvement for 71% of symptoms. "Given these superlative results, we think it is possible RLAY shares could exceed our anticipated >10% move as some investors may adopt VM as the main value driver," Leerink said. Since market open, the biotech's stock has risen 9% to $13.29 per share. The trial is testing doses of 100 mg, 300 mg and 400 mg twice daily. "We believe there is no further efficacy left on the table," Patel said about the 300-mg dosing regimen. "As you go above that, you're just seeing greater tolerability challenges, and so we don't think there's any room for us to go higher than 300." The rates of treatment-related adverse events (TRAEs) among 22 patients were "proportional to dose level," with no dose discontinuations, according to Relay. Two patients (9%) experienced a grade 3 or higher TRAE. Zovegalisib wasn't tied to rashes or stomatitis of any grade, and no cases of grade 3 or higher hyperglycemia or diarrhea were reported, though the biotech did not disclose all the data for adverse events. Overall, zovegalisib's tolerability profile was generally "as expected and consistent with mutant-selective PI3Kα inhibition," according to Relay. The rates of key adverse events such as hyperglycemia, stomatitis and rash were lower than or similar to Vijoice, according to Leerink. Based on the newest findings, Relay is opening multiple expansion cohorts at 400 mg once a day and 300 mg twice daily in patients 12 years and older, with a dose-finding trial for patients aged six to 11 years ongoing. Zovegalisib is also in later-stage testing for multiple metastatic breast cancers.
Relay Therapeutics missed first-quarter earnings expectations, with revenues of $3.0 million falling 35% short of forecasts and statutory losses of $0.41 per share exceeding estimates by 15%. Following the results, seven analysts cut their revenue forecasts for 2026 to $8.54 million, representing a 20% year-on-year decline, down from previous expectations of $9.68 million. Loss per share estimates increased slightly to $1.55 from $1.51. Despite the weaker outlook, the average price target rose 17% to $21.00, suggesting confidence in longer-term performance. Analyst valuations range from $18.00 to $25.00 per share. The forecast 26% annualised revenue decline compares unfavourably to the broader industry's expected 21% annual growth, though it represents an improvement on Relay Therapeutics' historical 39% annual revenue shrinkage over the past five years.